Singapore, June 13 -- ZeroHarm Sciences, India's pioneering clean-label nutraceutical company, is embarking on an aggressive global expansion, targeting the United Kingdom and GCC markets, including the UAE and wider Middle East.

Riding a 10x revenue growth over the past two years and operating at a strong ~20% EBITDA margin, the startup aims to double its revenue by FY 2026. This move builds on its growing success in the United States, which now contributes nearly 30% of its total revenue.

At the heart of ZeroHarm's global success is its patented ZeroHarm BioEnhance platform, a pharma-grade nanotechnology that encapsulates plant-based actives at the nanoscale, dramatically enhancing their bioavailability by up to 5x, ensuring faster on...